About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

10mil T trade due to rollover, I assume its today

here we go, about to go blue!!!!

City Equities

EiRx can spot the difference
Developing potential cancer treatments has become somewhat of a holy grail amongst biotech companies, but it is eirxs expertise in
apoptosis that the Board believes sets it apart from the pack. EiRx was formed in 1999 and debuted on AiM in 2004. Focusing on cancer therapies, with par-ticular attention on breast and colorectal cancer, the Company aims to leverage its knowledge of the Apoptosis process by which cells die in a reg- ulated manner and are absorbed into the body. This aim is also assisted by use of the Companys two core technologies. These are the ALiBi plat- form and the Engineered Pathway Dependence Screening Platform, or EnPAD, which have been developed to find and develop genes involved in the early stages of apoptosis that could become targets for novel therapeutic treatments. it could certainly be said that the potential mar- ket for a company engaged in this kind of work is considerable, especially when it is estimated* that up to 70% of all human diseases have some sort of defect in apoptosis control. EiRx currently has more than 15 patent applications pending in both the UK and US and a further development to the story came in September, when the Company announced that trials con- ducted on mice had shown a 50% reduction in breast tumour volumes, with good tolerance to the compound and no toxic or side effects. Pro- fessor Tom Cotter, CEO, commented at the time a reduction in tumour volume of 50% is seen by the National Cancer institute in America and
other leading authorities as being highly signifi- cant. it was estimated* that 443,000 women in 2004, across the seven major markets had developed breast cancer and forecasts indi- cated an annual increase to this at a rate of 3%. When you also consider colorectal cancer is the number two cause of cancer related deaths worldwide, EiRxs focus seems to be timely. it is therefore obvious that a therapy, which suc- cessfully differentiates between cancerous and non-cancerous cells has huge potential and we look forward to further updates as development continues in this worthwhile cause.
(*Source: EiRx Therapeutics) n eIrx THerAPeuTIcS
Status AIM
Code ERX.L
Recent Price 0.25p (0.22p-0.28p)
High 0.33p
Low 0.13p
Market Cap 6.8m

http://www.cityequities.com/campaigns/t!ps002/landing.asp

Driver
It was one of about ten pharma recommendations though.

laurie
Fair point but only a couple of months ago it was only the small punter that new about ERX, now D/Express, FT, City Equities who will be next all looking good for the coming weeks.

about to rocket

I'm predicting bonfire night.

HOPE YOU LOT ARE RIGHT WITH ALL THE HYPE I,AM HOLDING 5M @ .0018p-0025p ?

I have 34mil.. at ave of 25

GOOD LUCK POTHEAD

news out tomorrow 700202

27Mil + shares traded today & the price dosn't change Amazing!!!

PH - Are you applying the 'If I say it enough times, I'll be right once' philosophy?

To my recall, I don't think there has been a single occasion of your announcement of iminent news due to have ever been right!

POTHEAD I HEARD THE SAME BUT DO NOT LIKE POSTING RUMOURS I LIKE FACT LOT OF TRADES BUT NOT OF MONEY INVOLVED

large order being worked.. by the way starfrog, shows how much you know mate.

PH surprise us and tell us it's going down we'll make a fortune!!!!!!

down on what ;-)

The sp!

Is the 10mil Trade a buy or sell?

Definitely a buy. 33k